Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody drug takes aim at autoimmune diseases

NCT ID NCT06647069

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Participants will be followed for about 13 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SAR448501 (also called DR-0201), a bispecific antibody

What this could lead to

If it works, this could point toward a new treatment option for lupus and rheumatoid arthritis that targets the immune system more precisely.

What could go wrong

This is a very early Phase 1 trial with only 62 people, focused on safety and dosing. It may not show clear benefit, and side effects are unknown. Many early-stage drugs do not advance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital lobar emphysema cutaneous lupus erythematosus dermatomyositis diffuse cutaneous systemic sclerosis polymyositis rheumatoid arthritis scleroderma Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLE CUTANEOUS LUPUS DCSSC DERMATOMYOSITIS DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS POLYMYOSITIS PRIMARY SJÖGREN SYNDROME RHEUMATOID ARTHRITIS (RA SCLERODERMA SJOGREN'S SYNDROME SLE SLE (SYSTEMIC LUPUS) SSC, DIFFUSE SCLEROSIS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 001-201

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Investigational Site Number : 001-203

    RECRUITING

    Brisbane, Queensland, 4151, Australia

  • Investigational Site Number : 001-301

    RECRUITING

    Auckland, 0622, New Zealand

  • Investigational Site Number : 001-401

    RECRUITING

    Sarajevo, 71000, Bosnia and Herzegovina

  • Investigational Site Number : 001-801

    RECRUITING

    Pretoria, 0002, South Africa

  • Investigational Site Number : 001-803

    RECRUITING

    Pretoria, 0184, South Africa

  • Investigational Site Number : 001-804

    RECRUITING

    Vereeniging, 1935, South Africa